LEKADOL COMBO 500 mg/ 12,2 mg prašek za peroralno raztopino Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lekadol combo 500 mg/ 12,2 mg prašek za peroralno raztopino

lek d.d. - fenilefrin; paracetamol - prašek za peroralno raztopino - fenilefrin 10 mg / 1 vrečica  paracetamol500 mg / 1 vrečica; paracetamol 500 mg / 1 vrečica - paracetamol, kombinacije brez psiholeptikov

Vesicare 1 mg/ml peroralna suspenzija Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

vesicare 1 mg/ml peroralna suspenzija

astellas pharma d.o.o. - solifenacin - peroralna suspenzija - solifenacin 0,75 mg / 1 ml - solifenacin

Blincyto Evropska unija - slovenščina - EMA (European Medicines Agency)

blincyto

amgen europe b.v. - blinatumomab - predkroglomerna limfoblastna levkemija limfoma - antineoplastična sredstva - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.